Trial Profile
Phase II study to evaluate the efficacy and tolerability of fulvestrant 250mg, 250mg (plus 250mg loading regimen) and 500mg in postmenopausal women with ER +ve advanced breast cancer progressing or relapsing after previous endocrine therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2016
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms FINDER-I
- Sponsors AstraZeneca
- 14 Feb 2012 Actual end date (1 Feb 2012) added as reported by ClinicalTrials.gov.
- 14 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Aug 2011 Planned end date changed from 1 Aug 2009 to 1 Mar 2012 as reported by ClinicalTrials.gov.